Antares Pharma announcse update to QuickShot testosterone program Antares Pharma announced that a meeting was held with the U.S. Food and Drug Administration to discuss a registration study for the VIBEX QuickShot auto injector in testosterone deficient adult males. The study will include approximately 150 adult males with testosterone blood levels less than 300 ng/dL, and will begin recruitment in the third quarter of 2014. The study is designed to show that once-weekly self-administration of testosterone with the VIBEX QuickShot auto injector can safely achieve normal blood levels of testosterone in hypogonadal men.
News For ATRS From The Last 14 Days
Check below for free stories on ATRS the last two weeks.